CDK4 and breast carcinoma: [51, 52] However, there are still certain patients who benefit from node dissection such as young patients in which chemotherapy is associated with survival benefit in node positive disease and in ER+ breast cancer in which CDK4/6 inhibitor may be of benefit[53, 54].